(Q36641817)

15 August 2017

The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma (English)

1 reference

15 August 2017

1 reference

1 reference

McClay EF

1

1 reference

15 August 2017

McClay ME

2

1 reference

15 August 2017

Monroe L

3

1 reference

15 August 2017

Baron PL

4

1 reference

15 August 2017

Cole DJ

5

1 reference

15 August 2017

O'Brien PH

6

1 reference

15 August 2017

Metcalf JS

7

1 reference

15 August 2017

Maize JC

8

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 July 2000

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

83

1 reference

15 August 2017

1

1 reference

15 August 2017

16-21

1 reference

https://scigraph.springernature.com/pub.10.1054/bjoc.1999.1220

15 August 2017

0 references

cites work

Systemic treatments for advanced cutaneous melanoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374536

Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374536

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374536

Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374536

Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374536

Model predicting survival in stage I melanoma based on tumor progression

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374536

Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374536

Effective chemotherapy for melanoma after treatment with interleukin-2

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374536

Treatment of Stage IV Malignant Melanoma with Dacarbazine, Carmustine, Cisplatin, and Tamoxifen Regimens: A University of South Florida and H. Lee Moffitt Melanoma Center Study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374536

Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374536

Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374536

Tamoxifen modulation of cisplatin resistance in patients with metastatic melanoma. A biologically important observation

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374536

Tamoxifen modulation of cisplatin cytotoxicity in human malignancies

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374536

The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374536

A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374536

Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374536

Modulation of cisplatin resistance in human malignant melanoma cells

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374536

Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatment in a randomised multicentre study (EORTC Protocol 18781).

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374536

Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen

20 September 2018

1 reference

12 December 2020

Adjuvant chemotherapy with dacarbazine, vindesine, and cisplatin in pathological stage II malignant melanoma

1 reference

12 December 2020

Results of adjuvant interferon study in WHO melanoma programme

1 reference

12 December 2020

Clinical and histologic involvement of regional lymph nodes in malignant melanoma. Adjuvant vindesine improves survival

1 reference

12 December 2020

Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma

1 reference

12 December 2020

Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group

1 reference

12 December 2020

Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma

1 reference

12 December 2020

Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma

1 reference

12 December 2020

Identifiers

DOI

10.1054/BJOC.1999.1220

1 reference

Dimensions Publication ID

15 August 2017

0 references

1 reference

15 August 2017

PubMed publication ID

10883662

1 reference